Holen Sie sich die Stockscreener-App
540.03
0.62%
-3.37
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
Liquidia Shares Surge 42.48% After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Just Paid $380 Million to End a Patent War That Crushed the Stock - Money Morning
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH - The Manila Times
Patients with high blood pressure in the lungs will keep access to YUTREPIA as Liquidia settles six lawsuits. - Stock Titan
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in shares - Investing.com
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 12 October - Investing.com Canada
The CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
After exercising options at $117.76, the CEO's trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics Corporation Presents New Data Across Its Commercial and Development Portfolio At the CHEST 2026 Annual Meeting - marketscreener.com
An inhaled drug still being tested reduced the risk of multiple worsening events for people with lung scarring - Stock Titan
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting - Yahoo Finance
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com UK
United Therapeutics CEO Rothblatt sells $5.2m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.2m in stock - Investing.com
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com Nigeria
United Therapeutics CEO Martine Rothblatt sells $5.1m in shares - Investing.com
Form 4 United Therapeutics Corporation For: 10 October By Investing.com - Investing.com Nigeria
Is United Therapeutics Corp (UTHR) Overvalued After 3.1% Rally? - GuruFocus
After exercising 9,500 options, the CEO’s trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
McDermott team recognized by Law.com’s Litigation Daily for patent trial win for United Therapeutics - McDermott Will & Schulte
United Therapeutics chairperson & CEO Martine Rothblatt sells $5.2m in stock - Investing.com
The CEO's family trust exercises options and sells 9,500 United Therapeutics (UTHR) shares under a trading plan. - Stock Titan
LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Family trusts sell 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
United Therapeutics Wipes Sandoz $70.6 Million Remodulin Win (1) - Bloomberg Law News
After exercising options at $117.76 per share, United Therapeutics (UTHR) CEO trust sells 9,500 shares. - Stock Titan
CEO trusts sold 9,500 United Therapeutics (UTHR) shares after exercising options at $117.76 each. - Stock Titan
After exercising 9,500 options, a CEO family trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics chairperson & CEO Rothblatt sells $1.06m - Investing.com
United Therapeutics EVP sells $4.69m in shares after option exercise - Investing.com
United Therapeutics CEO Martine Rothblatt disposes of $3.9m in stock - Investing.com
An 8,300-share sale followed an option exercise by United Therapeutics (UTHR) counsel Paul A. Mahon. - Stock Titan
Family trusts sell 1,920 United Therapeutics (UTHR) shares under CEO Rothblatt's trading plan. - Stock Titan
CEO family trusts sell 7,580 shares as United Therapeutics (UTHR) reports a 9,500-option exercise. - Stock Titan
United Therapeutics Jumps 13% After Court Backs Key Patent Claims Against Liquidia - finance.biggo.com
United Therapeutics Corp Stock (UTHR) Moved Up by 7.26% on Oct 1: What Investors Need To Know - tradingkey.com
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% - Zacks Investment Research
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia - Benzinga
Why is United Therapeutics stock gaining today? - Investing.com
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last? - Zacks Investment Research
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last? - Yahoo! Finance Canada
United Therapeutics Corporation wins Yutrepia PH‑ILD patent ruling - Mugglehead Investment Magazine
United Therapeutics Soars 13% as Court Rules Yutrepia Infringes Its Patent - Yahoo Finance
1.10%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):